RA Capital Healthcare Fund LP 的 Form 4/A 修正申報
修正Artiva Biotherapeutics, Inc.（ARTV），2026/7/23 申報
- 申報編號
- 0001231919-26-000790
- 申報時間
- 2026/7/23 21:21 ET
- 交易日
- 2026/7/13
- 申報延遲
- 10 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2026/7/14
這份申報列了 1 筆非衍生性交易。沿用原件裡沒有重述的 1 筆交易。公開市場買進合計 $19.4 萬。交易後 10 天申報。
這份修正申報重述了 0001231919-26-000764（2026/7/14 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | 董事、持股 10% 以上大股東 |
| Ra Capital Management, L.P.CIK 0001346824 | 董事、持股 10% 以上大股東 |
| Kolchinsky PeterCIK 0001384859 | 董事、持股 10% 以上大股東 |
| Shah Rajeev M.CIK 0001619841 | 董事、持股 10% 以上大股東 |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | 董事 |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/13 | Common Stock | P買進取得 | +6,522 | $8.94F2 | +$58,306.68 | 16,817,543 | 間接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001231919-26-000764（2026/7/14 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/10 | Common Stock | P買進取得 | +15,102 | $8.97F1 | +$135,464.94 | 16,811,021 | 間接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
This Form 4/A amends the Form 4 filed on July 14, 2026 to correct the number of shares purchased, which were reported as 6,552, due to a clerical error.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F4
Held directly by the Fund.